Home/Health Plans/Employers/OnTrak Members/Contact Us
/
         
Blog Home  
  » Home  
  Recent Posts  
 
 
 
  Blog Calendar  
 
SuMoTuWeThFrSa
   1234
567891011
12131415161718
19202122232425
262728293031 
 
  Catasys Newsletter  
  Get the latest in healtcare news. » Sign Up Now  

Welcome to the Catasys On Healthcare Blog
Substance dependence drives significant health care costs for payors through a combination of factors that include acute inpatient utilization and unaddressed co-morbidities. The Substance Dependence problem is pervasive, largely untreated and costly. Stay informed on these topics by visiting our blog periodically. You can also sign up for the Catasys On Healthcare Newsletter to receive the latest in health care news. » Sign Up for Newsletter


Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Flumazenil and Gabapentin in Reducing Craving and Use During use during Initial Treatment of Methamphetamine Dependence

Catasys Health - Wednesday, November 25, 2009

Harold Urschel, Research Across America, Dallas, Texas
Published in the Journal of Psychopharmacology, November 25, 2009
 » More


Raymond Anton, Medical University of South Carolina, Charleston, SC

Catasys Health - Saturday, August 01, 2009

Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence
Published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.

 The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo.

Among members with more symptoms of alcohol withdrawal, the Prometa group experienced: » More
| 1 |

 
 
  Tags
 
SD members Health Care Utilization Opioid Medications care coaching behavioral health naloxone drug addiction alcohol drinking vivitrol sober medical and behavioral costs hospital drug addicts Co Occurring Disorders nicotine Raymond Anton sugar behavioral healthcare social network Research Across America flumazenil addict binge drinking stimulants health insurance medical costs opioid-drug interactions prometa oxycodone psychosocial overdose dependence issues substance dependence health insurance codeine behavioral healthcare services Harold Urschel opiod-based stratified substance use disorder CIWA randomized medical Opioid Prescribing double-blind marijuana SD health insurance heroin recovery placebo diabetes opiod abuse reducing craving health plan percocet Opioid Treatment placebo-controlled communication muscle relaxant sobriety alcohol treatment health reform drug abuse substance dependence costs identification PTSD withdrawal physician- patient relations pain killers alcohol Journal of Psychopharmacology primary care OxyContin pain medication emergency room smoking craving score prescriptions fentanyl cocaine treatment high-utilizing drug treatment craving gabapentin mental illness data mining behavioral health care services over-the-counter substances narcotic bipolar disorder reduction in use stress methadone treatment opioid overdose urine drug screen addiction depression addiction treatment meth relapse painkillers contract UnitedHealthcare depression screening opioid antagonist behavioral health care opioid drug overdose cigarettes drug use post-traumatic stress disorder anxiety hydrocodone Catasys morphine alcoholism mental health ADHD recovery network cocaine suboxone chronic pain opiates hospitalizations trauma methamphetamine dependence methamphetamine buprenorphine alcohol dependence predictive modeling relapse prevention ADD OnTrak vicodin pain pills opioid abuse substance dependence ER facebook drinking reduction in craving
  Call Us Today
  866-517-1414
         
 
 
Home/News/Press/Investor Relations/Careers/BlogContact Us/Site Index/Privacy Policy/Photo Disclaimer
 
  Copyright © 2013 Catasys. All rights reserved. | 11150 Santa Monica Blvd., Suite 1500, Los Angeles, California 90025 | Toll Free: 1-866-517-1414